BACHEM AMERICAS INC

Bachem Americas Inc. specializes in the current Good Manufacturing Practice (cGMP) production of complex peptide-based drug substances and associated chemistry, manufacturing, and controls (CMC) services for biopharmaceutical development. The company delivers end-to-end support for stability studies, process validation, and scale-up of active pharmaceutical ingredients, with demonstrated expertise in producing clinical-grade peptides such as PTH-IA under stringent regulatory standards. Their technical capabilities include synthetic peptide manufacturing, analytical method development, impurity profiling, and formulation support tailored to investigational new drug (IND) and biologics license application (BLA) pathways. Bachem’s differentiation lies in its precision manufacturing of structurally complex peptides under cGMP conditions, ensuring batch consistency and compliance with FDA and ICH guidelines for use in therapeutic applications. The company maintains a consistent relationship with the Department of Health and Human Services, providing critical CMC services that support the development of novel biologics and peptide therapeutics. Their work directly enables clinical-stage programs by delivering high-purity drug substances and comprehensive stability data required for regulatory submissions. Bachem Americas operates within the Medicinal and Botanical Manufacturing NAICS category, focusing exclusively on the synthesis and production of advanced therapeutic peptides rather than broad pharmaceutical manufacturing. This narrow specialization positions them as a niche provider for biotech and pharmaceutical firms requiring high-quality, small-scale peptide production under cGMP. As a 2L entity headquartered in Torrance, California, Bachem Americas is a focused manufacturer with no public certifications on record. Its geographic presence in Southern California supports proximity to key biotech hubs and federal research partners, reinforcing its role as a specialized supplier within the U.S. government’s biopharmaceutical development ecosystem.